Joseph Todisco - Mar 1, 2022 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Executive Vice President
Signature: /s/ Meredith Cook, Attorney-in-Fact
Stock symbol: AMRX
Transactions as of: Mar 1, 2022
Transactions value $: -$58,905
Form type: 4
Date filed: 3/3/2022, 08:22 PM
Previous filing: Mar 1, 2022
Next filing: Mar 22, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Options Exercise		+11.1K	+3.7%		311K	Mar 1, 2022	Direct	F1, F2
transaction	AMRX	Class A Common Stock	Tax liability	-$17.4K	-3.91K	-1.26%	$4.45	307K	Mar 1, 2022	Direct	F3
transaction	AMRX	Class A Common Stock	Options Exercise		+26.5K	+8.64%		334K	Mar 1, 2022	Direct	F1, F2
transaction	AMRX	Class A Common Stock	Tax liability	-$41.5K	-9.33K	-2.8%	$4.45	324K	Mar 1, 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-11.1K	-50%	$0.00	11.1K	Mar 1, 2022	Class A Common Stock	11.1K		Direct	F2, F4
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-26.5K	-25%	$0.00	79.6K	Mar 1, 2022	Class A Common Stock	26.5K		Direct	F2, F5
transaction	AMRX	Restricted Stock Units	Award	$0	+145K		$0.00	145K	Mar 3, 2022	Class A Common Stock	145K		Direct	F2, F6
transaction	AMRX	Performance-Based Restricted Stock Units	Award	$0	+290K		$0.00	290K	Mar 3, 2022	Class A Common Stock	290K		Direct	F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2	Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock.
F3	Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4	On March 1, 2019, the reporting person was granted 44,444 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F5	On March 1, 2021, the reporting person was granted 106,178 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F6	The restricted stock units vest in four equal annual installments beginning on March 3, 2023.
F7	Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F8	Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period.